Abbott Laboratories (ABT): Is Boston Scientific Corporation (BSX) Destined for Greatness?

Page 2 of 2

Boston Scientific Corporation (NYSE:BSX)’s management has also blames weakness in its interventional cardiology and cardiac rhythm management businesses for low overall sales growth in the latest quarter. However, Boston Scientific is forging ahead with clinical trials for optical nerve stimulation treatments for chronic migraines, in conjunction with existing anti-migraine medication. This clinical trial may open enormous opportunities, if it can reach a fairly substantial subset of the population that suffers from chronic migraines.

Boston Scientific has also forged ahead with testing on its WallFlex Biliary RX self-expanding metal stent, has positive data on its Watchman stroke-prevention device, and earned CE Mark approval for its next-generation bio-absorbable stent. Fool contributor Dan Carroll doesn’t think that this stent (the Synergy) is a better alternative to Abbott Laboratories (NYSE:ABT)‘ aptly named Absorb stent, but if it’s cost-competitive, safe, and effective, it should still claim a slice of this growing market

Putting the pieces together
Today, Boston Scientific Corporation (NYSE:BSX) has some of the qualities that make up a great stock, but no stock is truly perfect. Digging deeper can help you uncover the answers you need to make a great buy — or to stay away from a stock that’s going nowhere.

The article Is Boston Scientific Destined for Greatness? originally appeared on Fool.com and is written by Alex Planes.

Fool contributor Alex Planes and The Motley Fool have no position in any of the stocks mentioned.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.


Page 2 of 2